跳至主要内容
临床试验/ACTRN12614001201662
ACTRN12614001201662已完成未知

Safety and cost-effectiveness of Ganoderma lucidum (Reishi mushroom) compared to Ceratonia siliqua in patients with Fibromyalgia: a double-blind, randomised, pilot trial.

Francesco Pazzi0 个研究点目标入组 66 人开始时间: 2014年11月14日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1. Be diagnosed with fibromyalgia;
  • 2. Be able to communicate effectively with study staff;
  • 3. Be aged more than 18 years;
  • 4. Give written informed consent.

排除标准

  • 1. Be pregnant;
  • 2. Change the daily life habits during the six weeks of treatment;
  • 3. Take immunosuppressive;
  • 4. Suffer diabetes;
  • 5. Participating in other studies;
  • 6. Take C vitamin supplementation;
  • 7. Take anticoagulants;
  • Patients may abandon the trial if some circumstances happen: they withdraw informed consent, the researcher or their general practitioner feel that they should withdraw from the study for reasons of safety and the patient does not comply with the treatment for more than 80% of the dose.

研究者

发起方
Francesco Pazzi

相似试验